Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Sano S, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. J Dermatol. 2023 Feb;50(2):e41-e68. doi: 10.1111/1346-8138.16691. Epub 2022 Dec 29. J Dermatol. 2023. PMID: 36582113
This is the English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti-tumor necrosis factor-alpha antibodies, became available in the field of dermatolog …
This is the English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). As the first biologics for …
English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Takahashi K, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. J Dermatol. 2023 May;50(5):e138-e150. doi: 10.1111/1346-8138.16797. Epub 2023 Apr 1. J Dermatol. 2023. PMID: 37132187
This guidance was developed for board-certified dermatologists who specialize in the treatment of psoriasis and to promote the proper use of oral JAK inhibitors. In the package inserts and guides for appropriate use, upadacitinib and deucravacitinib are classified as a "JA …
This guidance was developed for board-certified dermatologists who specialize in the treatment of psoriasis and to promote the proper …